Ohio medical practice reveals expansion plan

November 20, 2018

BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities. Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in […]

Read the full article →

EXCLUSIVE: Cincinnati medical practice reveals expansion plan

November 15, 2018

BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities. Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in […]

Read the full article →

Addiction Treatment Gap Is Driving A Black Market For Suboxone

October 6, 2018

This medicine to treat opioid addiction is hard to come by — only a fraction of doctors are approved to prescribe it. So some people trying to quit a heroin habit turn to a black market for help.(Image credit: Craig F. Walker/The Boston Globe/Getty Images) (Source: NPR Health and Science) MedWorm Message: Have you tried […]

Read the full article →

Cassipa (Buprenorphine and Naloxone Sublingual Film) – new on RxList

September 20, 2018

(Source: RxList – New and Updated Drug Monographs) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →

Teva wins FDA nod for sublingual film to treat opioid dependence

September 11, 2018

The FDA last week approved Teva Pharmaceuticals’ Cassipa buprenorphine and naloxone sublingual film as a maintenance treatment for opioid dependence. There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams buprenorphine and 4 milligrams of naloxone, bringing a […]

Read the full article →

Cassipa Approved for Opioid Dependence

September 11, 2018

MONDAY, Sept. 10, 2018 — Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the agency said in a news release. Both buprenorphine and naloxone have been approved… (Source: Drugs.com – Daily MedNews)

Read the full article →

FDA Approves New Treatment for Opioid Dependence

September 11, 2018

MONDAY, Sept. 10, 2018 — Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the U.S. Food and Drug Administration said in a news release. Both buprenorphine and… (Source: Drugs.com – Pharma News) MedWorm Message: Have you tried our new medical search engine? More […]

Read the full article →

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

September 9, 2018

FDA approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. (Source: Food and Drug Administration) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →

Buprenorphine/Naloxone Rx Fills Up With Medicaid Expansion

August 29, 2018

TUESDAY, Aug. 28, 2018 — There was an increase in buprenorphine with naloxone fills in expansion versus nonexpansion counties after Medicaid expansion, according to a study published online Aug. 17 in JAMA Network Open. Brendan Saloner, Ph.D., from… (Source: Drugs.com – Pharma News) MedWorm Message: Have you tried our new medical search engine? More powerful […]

Read the full article →

Prescriptions for opioid use disorder treatment, opioid pain relievers after ACA Medicaid expansion

August 18, 2018

(JAMA Network) Medicaid expansion under the Affordable Care Act (ACA) was associated with an overall increase   in people filling prescriptions for buprenorphine with naloxone, which is a treatment for opioid use disorder, as well as an increase in people filling prescriptions for opioid pain relievers (OPRs) paid for by Medicaid in a data analysis […]

Read the full article →

← Previous Entries

Next Entries →